Calprotectin as an index of draining tunnel (dT) formation in Hidradenitis Suppurativa

13. Feb 2024 | 5 min read

Calprotectin as an index of draining tunnel (dT) formation in Hidradenitis Suppurativa

The complexity of the skin disease Hidradenitis Suppurativa (HS) and the role of proinflammatory signalling in this disease were extensively discussed at the 13th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) in Lyon, France.

Gentian has, in collaboration with Professor Evangelos Giamarellos-Bourboulis from the University of Athens, initiated a study to explore the correlation of circulating calprotectin levels with the activity and severity of the disease. The circulating calprotectin levels were measured with the Gentian GCAL® Calprotectin Immunoassay. Data from the study was presented at the EHSF conferences as a poster.

 

The importance of early biological treatment in Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic autoinflammatory skin condition impacting the apocrine sweat glands. Draining tunnel (dT) formation is the hallmark of HS in the affected skin. The disease can cause severe scarring and disability, placing a significant and often underestimated burden on patients. Diagnosis is mainly relying on patient reporting and visible outbreaks. A biomarker which predicts dT formation before their appearance in the skin could become a valuable tool for early biological treatment.

“Early intervention in HS is crucial to prevent the formation of severe scars in affected skin but predicting the course and advancement of the disease is challenging.“

Aleksandra Havelka, CSO, Gentian Diagnostics

 

The study – Calprotectin as a biomarker of severe inflammation and draining tunnel formation in hidradenitis suppurativa

Circulating calprotectin has been proven as an early biomarker for detection of inflammation and estimation of disease activity in various inflammatory conditions. Building on this previous knowledge of calprotectin in inflammatory conditions, the study in Athens aims to elucidate the value of calprotectin in HS disease classification and estimation of disease severity, prediction of development of draining tunnels and treatment monitoring.

Data presented at the EHSF conference confirms the correlation of calprotectin levels with the disease activity and severity of the disease, measured by number of draining tunnels and iHS4 (International HS 4 score). Calprotectin’s use as surrogate of early start of biologicals and response to treatment is subject of the currently ongoing part of the study.

"We believe that calprotectin could serve as a valuable tool for the early identification of severe HS, offering guidance for treatment initiation and monitoring, and potentially preventing severe inflammation and development of extensive scarring in affected skin."

Aleksandra Havelka, CSO, Gentian Diagnostics

 

Gentian GCAL® Calprotectin Immunoassay

The Gentian GCAL® Calprotectin Immunoassay is the first turbidimetric assay for the quantitative measurement of calprotectin in plasma and serum intended as an aid in the detection and assessment of inflammation and inflammatory response to infections. The open channel assay can be applied on a wide range of automated clinical chemistry analysers.

GCAL® is CE-marked and IVDR certified.

 

plasma and serum calprotectin



Question about circulating calprotectin and GCAL®? 

Interested in plasma and serum calprotectin? Want to know more? Please send an email to marketing@gentian.com or fill out the form below:

 

 

blood calprotectin

 

This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances.

 

 

 

 

 

 

You may also read


Cystatin C testing - Balancing additional costs against potential benefits

Apr 11, 2024

Cystatin C testing - Balancing additional costs against potential benefits

The KDIGO (Kidney Disease: Improving Global Outcomes) 2024 Clinical Practice Guideline for the Evaluation and..

Scientists to Gentian’s R&D department

Apr 08, 2024

Scientists to Gentian’s R&D department

Scientists to Gentian’s application validation group We are looking for two new colleagues in the positions..

KDIGO CKD 2024 guidelines: Patients benefiting from combined cystatin C and creatinine

Apr 03, 2024

KDIGO CKD 2024 guidelines: Patients benefiting from combined cystatin C and creatinine

The global non-profit organisation KDIGO (Kidney Disease: Improving Global Outcomes), commits to create and..